Theralase Release FY2021 Audited Financial Statements
29 avr. 2022 21h11 HE
|
Theralase Technologies Inc.
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Bladder Cancer Detection Kit Market Size Worth USD 322 Million by 2027 at 11.17% CAGR - Report by Market Research Future (MRFR)
26 avr. 2022 15h47 HE
|
WantStats Research and Media Pvt. Ltd.
New York, US, April 26, 2022 (GLOBE NEWSWIRE) -- Bladder Cancer Detection Kit Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Bladder Cancer...
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
26 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
05 avr. 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research
15 févr. 2022 04h39 HE
|
Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...
Cancer Support Community Launches New Study Focused on Bladder Cancer
10 févr. 2022 16h25 HE
|
Cancer Support Community
PHILADELPHIA, PA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), the world’s largest provider of cancer support with a network of 175 locations across the United States and...
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
31 janv. 2022 13h00 HE
|
DelveInsight Business Research LLP
Las Vegas, USA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight Non-Muscle Invasive Bladder Cancer Pipeline...
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
05 janv. 2022 06h38 HE
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
20 déc. 2021 16h45 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
Theralase Expands Intellectual Property Portfolio
09 déc. 2021 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...